199 related articles for article (PubMed ID: 25576329)
21. Vildagliptin: a new oral treatment for type 2 diabetes mellitus.
Mathieu C; Degrande E
Vasc Health Risk Manag; 2008; 4(6):1349-60. PubMed ID: 19337548
[TBL] [Abstract][Full Text] [Related]
22. The effect of vildagliptin relative to sulfonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study.
Hassoun AA; Al-Arouj M; Ibrahim M
Curr Med Res Opin; 2017 Jan; 33(1):161-167. PubMed ID: 27684469
[TBL] [Abstract][Full Text] [Related]
23. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
24. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.
Dejager S; Razac S; Foley JE; Schweizer A
Horm Metab Res; 2007 Mar; 39(3):218-23. PubMed ID: 17373638
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study.
Iwamoto Y; Kashiwagi A; Yamada N; Terao S; Mimori N; Suzuki M; Tachibana H
Diabetes Obes Metab; 2010 Aug; 12(8):700-8. PubMed ID: 20590747
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting.
Melzer Cohen C; Davis C; Shalev V; Chodick G
J Diabetes; 2018 Jan; 10(1):68-72. PubMed ID: 28418203
[TBL] [Abstract][Full Text] [Related]
28. Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes.
Wang JS; Hung YJ; Lu YC; Tsai CL; Yang WS; Lee TI; Hsiao YC; Sheu WH
Diabetes Res Clin Pract; 2018 Apr; 138():119-127. PubMed ID: 29444447
[TBL] [Abstract][Full Text] [Related]
29. Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).
Hermans M; Van Gaal L; Rézette I; Daci E; MacDonald K; Denhaerynck K; Vancayzeele S; De Meester L; Clemens A; Yee B; Abraham I
Prim Care Diabetes; 2016 Dec; 10(6):425-433. PubMed ID: 27388795
[TBL] [Abstract][Full Text] [Related]
30. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
Garber AJ; Foley JE; Banerji MA; Ebeling P; Gudbjörnsdottir S; Camisasca RP; Couturier A; Baron MA
Diabetes Obes Metab; 2008 Nov; 10(11):1047-56. PubMed ID: 18284434
[TBL] [Abstract][Full Text] [Related]
31. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
Filozof C; Gautier JF
Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
[TBL] [Abstract][Full Text] [Related]
32. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus.
Kothny W; Foley J; Kozlovski P; Shao Q; Gallwitz B; Lukashevich V
Diabetes Obes Metab; 2013 Mar; 15(3):252-7. PubMed ID: 23039321
[TBL] [Abstract][Full Text] [Related]
33. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus.
Kikuchi M; Abe N; Kato M; Terao S; Mimori N; Tachibana H
Diabetes Res Clin Pract; 2009 Feb; 83(2):233-40. PubMed ID: 19118913
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data.
Kamenov Z
Diabetes Ther; 2014 Dec; 5(2):483-98. PubMed ID: 25245616
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
Lukashevich V; Schweizer A; Foley JE; Dickinson S; Groop PH; Kothny W
Vasc Health Risk Manag; 2013; 9():21-8. PubMed ID: 23378769
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Kim G; Oh S; Jin SM; Hur KY; Kim JH; Lee MK
Expert Opin Pharmacother; 2017 Aug; 18(12):1179-1186. PubMed ID: 28714741
[TBL] [Abstract][Full Text] [Related]
37. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Montilla S; Marchesini G; Sammarco A; Trotta MP; Siviero PD; Tomino C; Melchiorri D; Pani L;
Nutr Metab Cardiovasc Dis; 2014 Dec; 24(12):1346-53. PubMed ID: 25300980
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
[TBL] [Abstract][Full Text] [Related]
39. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.
Ning G; Wang W; Li L; Ma J; Lv X; Yang M; Wang W; Woloschak M; Lukashevich V; Kothny W
J Diabetes; 2016 May; 8(3):345-53. PubMed ID: 25929739
[TBL] [Abstract][Full Text] [Related]
40. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Bolli G; Dotta F; Colin L; Minic B; Goodman M
Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
